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PreviewsPNMT and KRT19, are respectively
involved in neuroendocrine differentiation
and epithelial-to-mesenchymal transition
(EMT). Interestingly, despite exhibiting a
decreased growth rate similar to the
Fh1/ mouse embryonic fibroblasts, the
Sdhb/ chromaffin cells showed mark-
edly increased migratory capacities,
potentially reflecting epigenetic deregula-
tion of EMT genes and the aggressive
nature of SDHB-related PCC/PGL.
Recently, inhibitors that specifically
target mutant IDH1 and IDH2 have been
reported. Such inhibitors could reverse
(R)-2HG-mediated epigenetic deregula-
tion, induce cell differentiation, and sup-
press the growth of IDH mutant tumor
cells (Kim and DeBerardinis, 2013).
Letouze´ et al. (2013) showed that tran-
sient treatment with a DNA methyltrans-
ferase inhibitor repressed the migration
capacities of Sdhb/ cells, implicating
the possibility of epigenetic targeting in
SDH-related tumors. However, succinate
and fumarate accumulation exert variousnonepigenetic cellular impacts, and, to
achieve therapeutic efficacy, a synergistic
lethality approach is probably desired.
Nonetheless, the emergence of epigenet-
ically silenced gene sets may serve as
useful biomarkers for early detection of
cancers characterized by Krebs cycle
defects.REFERENCES
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Activated STAT3 and increased expression of the histone methyltransferase EZH2 are independently asso-
ciated with the most malignant subset of gliomas. In this issue of Cancer Cell, Kim and colleagues discover
that EZH2 enhances STAT3 activation by trimethylating lysine180 in STAT3 and does so preferentially in
glioma stem-like cells.Presuming that cancer stem cells are
responsible for therapeutic resistance in
cancer patients, the discovery of the
molecular differences that drive cancer
stem cell phenotypes holds significant
value for improving therapy. More valu-
able still would be the ability to selectively
inhibit these molecular drivers of stem-
ness. In this issue of Cancer Cell, Kim
et al. (2013) employ cultures of glioma
stem-like cells (GSCs) and their isogenic
bulk tumor cells along with intracranial
xenografts and come one step closer to
achieving this ambitious goal.Mutation or overexpression of en-
hancer of Zeste homolog 2 (EZH2) can
drive the clonal expansion of leukemias
and the growth of solid cancers, though
individual EZH2 alterations follow diver-
gent paths toward malignancy. EZH2 is
most known as an enzymatically active
component of the Polycomb repressive
complex 2 (PRC2), which is responsible
for depositing methyl groups onto lysine
27 (K27) of histone H3 (H3K27). EZH2
plays an important role in maintaining
stem cell function. The most common
EZH2 mutations in cancer occur withinthe SET domain at Y641, which result in
increased trimethylation activity, leading
to an increase in global H3K27me3 levels
in B cell lymphomas (Yap et al., 2011). In
contrast, in breast cancer cells, AKT-
mediated phosphorylation of S21 reduces
EZH2 interaction with histone H3, leading
to a decrease in global H3K27me3 levels
(Cha et al., 2005). In addition, in pediatric
brain tumors, recurrent somatic mutation
of K27 on histone H3 variant H3F3A may
deplete H3K27me3 on canonical H3
indirectly because of increased interac-
tion between mutant H3F3A and EZH2.23, June 10, 2013 ª2013 Elsevier Inc. 711
EZH2
EZH2
AKT S21
P
STAT3
K180
M MM
S21
GSK126/EPZ005687
Histone H3
Glioma Stem-like Cell
Bulk Tumor Cell
Perifo
sine
Y705
P
M MM
K27
Figure 1. pS21-EZH2 Enhances STAT3 Activation through K180 Trimethylation in Glioma
Stem-like Cells
In GSCs, AKT phosphorylates S21 on EZH2, switching its substrate preference from H3K27 to STAT3 and
potentially other nonhistone proteins. K180 trimethylation of STAT3 results in increased STAT3 activation
via increased phosphorylation of Y705 by JAKs, promoting tumor growth. In bulk tumor cells, AKT-medi-
ated phosphorylation of EZH2 is diminished; EZH2with unphosphorylated S21 preferentially binds and tri-
methylates H3K27. Inhibitors such as GSK126 or EPZ005687 selectively target the methyltransferase
domain ofEZH2and, thus, canblockboth histone- andnon-histone-mediated routes forGBMprogression.
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PreviewsHowever, this occurs concurrently with
increased H3K27me3 colocalized with
EZH2 at specific genes associated
with tumorigenesis (Chan et al., 2013;
Lewis et al., 2013). These and other
studies suggest altered EZH2 function
contributes to tumor development by
promoting aberrant expression of cellular
oncogenes and tumor suppressor genes
via cancer-associated changes in H3K27
methylation.
Although not appreciated until
recently, EZH2 also methylates nonhis-
tone proteins. EZH2 monomethylates
transcription factors GATA4 and RORa
at lysines, resulting in a reduction in their
ability to activate transcription (He et al.,
2012; Lee et al., 2012). EZH2 also func-
tions in a PRC2-independent manner
as a transcriptional coactivator with
androgen receptor in castration-resistant
prostate cancer cells (Xu et al., 2012).
This raises the important questions of
whether EZH2 methylation of nonhistone
proteins may contribute to tumori-
genesis and how the balance of histone
and nonhistone methylation activity is
determined.
Kim et al. (2013) addressed these ques-
tions by first demonstrating that EZH2,
along with multiple members of the
PRC2 complex, interacts with STAT3.
Importantly, this interaction exists prefer-
entially in stem cells—specifically human
neural progenitor cells and GSCs, but712 Cancer Cell 23, June 10, 2013 ª2013 Elsneither in their differentiated isogenic
progeny nor in established glioma cell
lines grown in serum. STAT3 has a well
characterized role in cancer progression,
and its activation in glioblastoma multi-
forme (GBM) is associated with the
aggressive mesenchymal subtype and
poor overall survival (Carro et al., 2010).
The activation of STAT3 is dependent on
phosphorylation of Y705 by the Janus
kinases (JAKs), but STAT3 can also be
dimethylated at K140 by SET9, leading
to a decrease in activated STAT3 (Yang
et al., 2010). As with EZH2, STAT3 also
plays an important role in the mainte-
nance of GSCs. Therefore, the newly
discovered interaction between EZH2
and STAT3 might underlie a shared func-
tion in the maintenance of GSC pheno-
types. Inhibiting either of these proteins
could potentially help eradicate the GSC
pool within a GBM.
As a consequence of their interaction,
EZH2 trimethylatesSTAT3onK180,which
Kim et al. (2013) found to be essential for
STAT3 activation inGSCs andGBMxeno-
grafts. This is in contrast to EZH2-medi-
ated methylation of RORa or GATA4 or
SET9-mediated STAT3 K140 dimethyla-
tion, because these methyl group modifi-
cations result in a decrease in transcrip-
tional activity of the modified protein. The
exact mechanism by which trimethylation
at K180 contributes to STAT3 activation
and how this might synergize with Y705evier Inc.phosphorylation are not yet known.
Methylation at K140 on STAT3 can be
removed by LSD1 (Yang et al., 2010), but
it is unknown at this point which, if any,
protein(s) might be involved with the de-
methylation of K180. Temporal examina-
tion of the changing interaction and
posttranslational modifications during dif-
ferentiation of GSCs into non-stem cells
could provide insight into the relative
ordering of phosphorylation and methyl-
ation, the dynamics of EZH2-STAT3 inter-
action, and whether the loss of interaction
is a driving force or a consequence of dif-
ferentiation. It is also not yet clear if the
EZH2-STAT3 interaction leads to robust
STAT3 K180 methylation in normal neural
progenitor cells and if this is important
for neural progenitor function. It should
be noted that GSCs are specifically
enriched and maintained by culturing in
EGF, which prior studies show is a potent
inducer of STAT3 phosphorylation and
activation.
Kim et al. (2013) show that AKT phos-
phorylates EZH2 at S21 in GSCs and, as
shown for breast cancer cells, may enable
EZH2 to bind substrates other than
H3K27. In fact, approximately 90% of
primary GBMs have AKT activation. In
GSCs, AKT-induced phosphorylation of
EZH2 increased activation of STAT3 via
K180 trimethylation and decreased the
survival of mice bearing xenografts of
GSCs. These results underscore the
importance of AKT activation in GBM
and establish a pathway by which EZH2
can contribute to tumor growth indepen-
dent of, or in addition to, gain or loss of
H3K27me3 (Figure 1). However, in pri-
mary tumors, AKT is presumably active
in both GSC and bulk tumor cell popula-
tions. Therefore, it will be important to
determine why AKT-mediated S21 phos-
phorylation of EZH2 and subsequent
K180 methylation on STAT3 occurs pref-
erentially in GSCs.
Selective inhibition of STAT3 has
been difficult to achieve in patients with
cancer. The data from this new study
suggested that it might be possible
to decrease STAT3 activation by inhibit-
ing EZH2. Emerging selective small
molecule inhibitors of EZH2 (GSK126,
GSK343, GSK503, and EPZ005687) sup-
press the growth of lymphoma cell
lines and xenografts that have activat-
ing EZH2 mutations. Kim et al. (2013)
found that GSK126 decreased levels
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Previewsof phosphorylated STAT3 in GSCs. Sub-
stantial additional research is required to
determine if this early experimental suc-
cess will translate into notable clinical
response.
The findings of Kim et al. (2013) are
important, because they establish an
H3K27-independent role for EZH2 in
GBM through K180 trimethylation of
STAT3, which appears to be involved in
the aggressiveness of high-grade glioma
(Figure 1). Furthermore, the results pro-
vide a new understanding of regulatory
pathways that drive GSC phenotypes. If
these findings are relevant to cancer
stem cells in patients, STAT3 and/or
EZH2 will become even more attractive
targets for improving therapeutic re-
sponse and patient survival.REFERENCES
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There is much interest in defining the nutrient dependencies of cancer cells and their mechanisms of adap-
tation to nutrient depletion. In a recent issue of Cell, Leprivier and colleagues demonstrate that eEF2K, which
can inhibit translation elongation acutely during protein synthesis, is a critical switch in the survival versus
death fate of starved cancer cells.Cells and organisms have evolved exqui-
site mechanisms to acutely adapt to
fluctuations in nutrient availability. Star-
vation impinges on highly conserved
nutrient-sensing pathways, resulting in
an integrated and adaptive response
that includes an abrupt halt to
anabolic processes that consume nutri-
ents and energy. The mammalian target
of rapamycin complex 1 (mTORC1),
general amino acid control nonderepres-
sible 2 (GCN2), and AMP-dependent
protein kinase (AMPK) are the best
characterized of these nutrient sensors
(Yuan et al., 2013), all of which exert
acute control over protein synthesis
(Figure 1A), perhaps the most nutrient-and energy-costly of cellular processes.
It is now evident that cancer cells can
drive anabolic processes that promote
cell growth and proliferation in a manner
largely independent of normal growth
signals (Cantor and Sabatini, 2012).
Importantly, oncogenic events that
disconnect anabolic processes from
normal control mechanisms are likely
to render tumor cells more vulnerable
to the loss of specific nutrients. In a
recent study published in Cell, Leprivier
et al. (2013) find that the adaptation of
tumor cells to nutrient deprivation is
dependent on their ability to acutely
block translation elongation during pro-
tein synthesis.In an isogenic fibroblast model, Lepriv-
ier et al. (2013) found that oncogene-
transformed cells were much more
sensitive to severe nutrient depletion in
the form of complete removal of glucose,
amino acids, and serum. Surprisingly,
this susceptibility was not due to in-
creased ATP consumption as, unlike
nontransformed cells, the oncogene-
expressing cells somehow sustained
their ATP levels in the absence of nutri-
ents. This difference was also reflected
in a lack of activation of AMPK, which
is normally stimulated in response to
energy stress (defined as an increase
in the ratio of cellular AMP or ADP to
ATP) and plays a critical role in23, June 10, 2013 ª2013 Elsevier Inc. 713
